Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2Lymphoid 1

Conditions

Multiple Myeloma 32Neoplasms, Plasma Cell 6Recurrence 4Lymphoma 4Leukemia 3Hodgkin Disease 3Ovarian Neoplasms 2Lymphoma, Non-Hodgkin 2Leukemia, Plasma Cell 2Hematologic Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Participation 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1

Interventions

fludarabine phosphate 19fludarabine 18Cyclophosphamide 16Tacrolimus 12Whole-Body Irradiation 11Melphalan 11Mycophenolic Acid 10Bortezomib 9Busulfan 8trametinib 7Dexamethasone 7thymoglobulin 6Stem Cell Transplantation 6Lenalidomide 6Cyclosporine 6Sirolimus 5Nivolumab 5Methotrexate 5dabrafenib 4Rituximab 4Peripheral Blood Stem Cell Transplantation 4Granulocyte Colony-Stimulating Factor 4Antilymphocyte Serum 4Alemtuzumab 4daratumumab 3aldesleukin 3Thiotepa 3Specimen Handling 3Ipilimumab 3Interleukin-2 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × liposomal doxorubicin × Plasma cell × Clear all
NCT00051311 2021-09-09

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
62 enrolled 15 charts
LymphoidOther hematologic neoplasmPlasma cell

Hodgkin Disease, Leukemia, Lymphoma, Multiple Myeloma, Hematologic Neoplasms

NCT00750815 2014-01-20

Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
58 enrolled 11 charts
Other hematologic neoplasmPlasma cell

Multiple Myeloma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡